Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21743078 | 1.00 | CRBN (0.44) | CRBNCTSKMAOASMN1; SMN2ESR2 | |
| SCHEMBL2054713 | 0.81 | CRBN (0.51) | CRBNCTSKMAOASMN1; SMN2AR | |
| SCHEMBL21743083 | 0.80 | AR (0.36) | ESR2AR | |
| SCHEMBL21743081 | 0.80 | AR (0.36) | ESR2AR | |
| SCHEMBL21723342 | 0.77 | CRBN (0.43) | CRBNCTSKMAOASMN1; SMN2AR | |
| SCHEMBL1939047 | 0.73 | MEN1 (0.45) | CRBNCTSKMAOASMN1; SMN2AR | |
| SCHEMBL23329726 | 0.73 | AR (0.44) | CRBNCTSKMAOASMN1; SMN2AR | |
| SCHEMBL22557673 | 0.72 | ALDH1A1 (0.48) | CRBNCTSKMAOASMN1; SMN2ALDH1A1 | |
| SCHEMBL21742996 | 0.71 | PLCG1 (0.44) | CRBNMAOAESR2MEN1KMT2A | |
| SCHEMBL21742995 | 0.71 | PLCG1 (0.44) | CRBNMAOAESR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3837244-B1 | 1-METHYL-4-[(4-PHENYLPHENYL)SULFONYLMETHYL]CYCLOHEXYANOL AND 1-METHYL-4-[[4-(2-PYRIDYL)PHENYL]SULFONYLMETHYL]CYCLOHEXANOL COMPOUNDS AND THEIR THERAPEUTIC USE | ISTESSO THERAPEUTICS LTD (GB) | 2025-05-14 | — | — | EP | disclosed |
| US-12240814-B2 | 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use | ISTESSO THERAPEUTICS LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-20240182418-A1 | 1-Methyl-4-[(4-Phenylphenyl)Sulfonylmethyl]Cyclohexyanol And 1-Methyl-4-[[4-(2-Pyridyl)Phenyl]Sulfonylmethyl]Cyclohexanol Compounds and Their Therapeutic Use | Modern Biosciences Limited (GB) | 2024-06-06 | — | — | US | disclosed |
| US-11834414-B2 | 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use | Modern Biosciences Limited (GB) | 2023-12-05 | — | — | US | disclosed |
| US-20220363642-A1 | 1-METHYL-4-[(4-PHENYLPHENYL)SULFONYLMETHYL]CYCLOHEXYANOL AND 1-METHYL-4-[[4-(2-PYRIDYL)PHENYL]SULFONYLMETHYL]CYCLOHEXANOL COMPOUNDS AND THEIR THERAPEUTIC USE | ISTESSO THERAPEUTICS LIMITED (GB) | 2022-11-17 | — | — | US | disclosed |
| CN-112805270-A | 1-methyl-4- [ (4-phenylphenyl) sulfonylmethyl ] cyclohexanol and 1-methyl-4- [ [4- (2-pyridinyl) phenyl ] sulfonylmethyl ] cyclohexanol compounds and therapeutic uses thereof | 现代生物科学有限公司 | 2021-05-14 | — | — | CN | disclosed |
| WO-2020035560-A1 | 1-METHYL-4-[(4-PHENYLPHENYL)SULFONYLMETHYL]CYCLOHEXYANOL AND 1-METHYL-4-[[4-(2-PYRIDYL)PHENYL]SULFONYLMETHYL]CYCLOHEXANOL COMPOUNDS AND THEIR THERAPEUTIC USE | Modern Biosciences Limited (GB) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363642-A1 | 1-METHYL-4-[(4-PHENYLPHENYL)SULFONYLMETHYL]CYCLOHEXYANOL AND 1-METHYL-4-[[4-(2-PYRIDYL)PHENYL]SULFONYLMETHYL]CYCLOHEXANOL COMPOUNDS AND THEIR THERAPEUTIC USE | MALT1, BCL3, MCL1 | CRBN 1154/4885CTSK 1409/4885MAOA 1264/4885 |
| US-11834414-B2 | 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use | MALT1, BCL3, MCL1 | CRBN 1154/4885CTSK 1409/4885MAOA 1264/4885 |
| US-12240814-B2 | 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use | MALT1, BCL3, MCL1 | CRBN 1154/4885CTSK 1409/4885MAOA 1264/4885 |
| US-20240182418-A1 | 1-Methyl-4-[(4-Phenylphenyl)Sulfonylmethyl]Cyclohexyanol And 1-Methyl-4-[[4-(2-Pyridyl)Phenyl]Sulfonylmethyl]Cyclohexanol Compounds and Their Therapeutic Use | MALT1, BCL3, MCL1 | CRBN 1154/4885CTSK 1409/4885MAOA 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.